Clinical Trials
CARsgen and Dispatch Bio launch groundbreaking CAR T collaboration in China
CARsgen is working to transform outcomes for patients with solid tumors by advancing the potential of CAR T technologies
- By IPP Bureau
| January 15, 2026
CARsgen Therapeutics Holdings Limited and Dispatch Bio have announced a clinical collaboration to test a novel combination therapy for solid tumors, with a Phase 1 trial slated to begin in China in 2026.
The study will evaluate DISP-11, an investigational therapy combining Dispatch Bio’s first-in-class Flare platform—including the novel tumor-specific virus DV-10—with CARsgen’s zevorcabtagene autoleucel, a BCMA-targeting CAR T-cell therapy already approved in China for multiple myeloma by the National Medical Products Administration (NMPA).
"CARsgen is working to transform outcomes for patients with solid tumors by advancing the potential of CAR T technologies," said Zonghai Li, Founder, Chairman, CEO, and CSO of CARsgen.
"Dispatch's Flare platform offers a differentiated and highly complementary approach to expanding where and how CAR T can be applied, particularly for solid tumors lacking specific targets. We are excited to explore this combination as part of our broader efforts to unlock meaningful benefit for patients."
The trial will focus on patients with epithelial-origin solid tumors, which make up 90% of all solid tumors. Participants will first receive DV-10, followed by administration of zevor-cel.
"We are working to expand the impact of the Flare platform, and this collaboration represents a step forward in a region with infrastructure for efficient and impactful oncology development and significant unmet medical need," said Sabah Oney, CEO of Dispatch.
"CARsgen's scientific rigor and track record of rapid clinical advancement make them an ideal partner. As our second collaboration with a company that has successfully commercialized a CAR T therapy, this partnership reinforces the growing confidence in Flare's potential across a variety of immunotherapies and will help shape our global development strategy."
